Open OfferMay 11, 2026, 04:48 PM
ArriVent BioPharma Launches $250M ATM Stock Offering
AI Summary
ArriVent BioPharma, Inc. announced the filing of a prospectus supplement for its existing "at the market offering" (ATM Program). This program allows the company to offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000. The sales will be conducted through Jefferies LLC as the sales agent, pursuant to an Open Market Sale Agreement dated February 3, 2025.
Key Highlights
- ArriVent BioPharma may offer and sell common stock with an aggregate offering price of up to $250,000,000.
- The shares will be sold from time to time through Jefferies LLC as the sales agent.
- The offering is part of the Company's existing "at the market offering" (ATM Program).
- A prospectus supplement was filed on May 11, 2026, for the ATM Program.
- The program operates under an Open Market Sale Agreement dated February 3, 2025.